Clinical trial results have shown that TIL enrichment is a predictive response to the PD-1 antibody pembrolizumab, both in patients with HER2-positive BC (NCT02129556) or TNBC (KEYNOTE-086). The gene discussed is ERBB2; the disease is breast cancer.